1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,049 | 0,056 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Viva Biotech Holdings: Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future | 44 | PR Newswire | HONG KONG, March 28, 2024 /PRNewswire/ --
Highlights of the Annual Results as of December 31, 2023:
Revenue reached RMB2,155.6 million
Gross profit amounted to RMB738.5 million
Adjusted non-IFRS... ► Artikel lesen | |
| 28.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION ... | - | HKEx | ||
| 18.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 18.01. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 18.01. | VIVA BIOTECH (01873): POLL RESULTS OF THE EGM HELD ON JANUARY 18, 2024; AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 03.01. | VIVA BIOTECH (01873): COMPLETION OF FULL REDEMPTION OF US$280 MILLION 1.00 PER CENT GUARANTEED CONVERTIBLE BONDS DUE 2025 (STOCK CODE: 40514) | - | HKEx | ||
| 27.12.23 | VIVA BIOTECH (01873): COMPLETION OF DISCLOSEABLE TRANSACTION IN RELATION TO DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY | 1 | HKEx | ||
| 27.12.23 | VIVA BIOTECH (01873): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 27.12.23 | VIVA BIOTECH (01873): NOTIFICATION LETTER AND CHANGE REQUEST FORM TO REGISTERED SHAREHOLDERS | - | HKEx | ||
| 27.12.23 | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT THE EGM | 1 | HKEx | ||
| 27.12.23 | VIVA BIOTECH (01873): NOTICE OF EGM | - | HKEx | ||
| 27.12.23 | VIVA BIOTECH (01873): PROPOSED ADOPTION OF THE VIVA SHANGHAI PHASE I SHARE OPTION SCHEME AND THE VIVA SHANGHAI PHASE II SHARE OPTION SCHEME; PROPOSED ... | - | HKEx | ||
| 22.12.23 | VIVA BIOTECH (01873): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 22.12.23 | VIVA BIOTECH (01873): (1) PROPOSED ADOPTION OF THE VIVA SHANGHAI PHASE I SHARE OPTION SCHEME AND THE VIVA SHANGHAI PHASE II SHARE OPTION SCHEME; AND (2) ... | - | HKEx | ||
| 15.12.23 | VIVA BIOTECH (01873): CONNECTED TRANSACTION-MANAGEMENT CO-INVESTMENT AND DEEMED DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | 1 | HKEx | ||
| 15.12.23 | VIVA BIOTECH (01873): DISCLOSEABLE TRANSACTION-DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY | - | HKEx | ||
| 01.12.23 | VIVA BIOTECH (01873): CHANGE IN EXECUTIVE DIRECTOR'S RESPONSIBILITIES AND APPOINTMENT OF CO-CHIEF FINANCIAL OFFICER | - | HKEx | ||
| 21.11.23 | Viva Biotech Secures Approx. US$ 210M Funding | 1 | FinSMEs | ||
| 20.11.23 | VIVA BIOTECH (01873): PARTIAL REPURCHASE AND CANCELLATION OF US$280 MILLION 1.00 PER CENT GUARANTEED CONVERTIBLE BONDS DUE 2025 ON THE OPEN MARKET (STOCK ... | 1 | HKEx | ||
| 20.11.23 | VIVA BIOTECH (01873): COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY AND AUTOMATIC CONVERSION OF ... | - | HKEx |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,706 | -0,38 % | Valneva Aktie: Tief im Abwärtssog | Die Aktie von Valneva notiert aktuell bei einem Preis von 3,93 € und verzeichnete im Laufe der Woche einen Rückgang von 2,39%. Die abwärtsgerichtete Dynamik, die sich insbesondere am Montag durch einen... ► Artikel lesen | |
| NOVONESIS | 52,40 | +1,51 % | NASDAQ OMX Nordic: Change of name and ticker code for Novozymes (97/24) | The Extraordinary General Meeting (EGM) of Novozymes A/S (Novozymes) held on
March 4, 2024 approved a secondary name of the company Novonesis A/S. As a
consequence of the name change, Novozymes has... ► Artikel lesen | |
| GENMAB | 268,20 | -1,32 % | Genmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln | NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB), a Danish biotechnology firm, announced on Tuesday that the first-quarter sales of Darzalex, Daratumumab, have totaled $2.692 billion, as updated... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,438 | -1,85 % | Arbutus Biopharma Corporation: Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update | ||
| BEIGENE LTD ADR | 129,00 | +5,74 % | BeiGene, Ltd.: BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer | Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab's... ► Artikel lesen | |
| MOLECULIN BIOTECH | 4,100 | 0,00 % | Moleculin Biotech, Inc.: European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) | - Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,780 | +4,08 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| SINO BIOPHARM | 0,318 | +0,63 % | Aktienmarkt: Kurs der Aktie von Sino Biopharmaceutical im Minus (0,279 €) | An der Börse liegt die Aktie von Sino Biopharmaceutical gegenwärtig im Minus. Der jüngste Kurs betrug 0,28 Euro. Das Wertpapier von Sino Biopharmaceutical verzeichnet zur Stunde einen Abschlag von 4... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,894 | -0,45 % | Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment | BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| VERICEL | 42,400 | -0,93 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance | Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,712 | 0,00 % | MustGrow Biologics Corp.: MustGrow Biologics to Present at the Planet MicroCap Showcase | MustGrow Biologics to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024Saskatoon, Saskatchewan--(Newsfile Corp. - April 17, 2024)... ► Artikel lesen | |
| ZAI LAB LTD ADR | 14,400 | +2,13 % | ZAI LAB (09688): OVERSEAS REGULATORY ANNOUNCEMENT - FORM S-3 | ||
| CSTONE PHARMACEUTICALS | 0,105 | +2,94 % | CSTONE PHARMA-B (02616): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023 | ||
| AKEBIA | 1,272 | -0,70 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
| CASI PHARMACEUTICALS | 2,510 | +7,73 % | Casi Pharmaceuticals Announces Fourth Quarter And Full-year 2023 Business And Financial Results | BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,004 (+7,87 %) liegt der Kurs bei 0,048 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
